$TLRY

Gendel Mitchell purchased $11K of TLRY

Gendel Mitchell (Global General Counsel) purchased 2,500 shares of Tilray Brands, Inc. (TLRY) at $4.43 on 2026-08-06.

Original reporting
SEC EDGAR · Gendel Mitchell
Published Aug 7, 2026, 1:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 2:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TLRY
Neutral
low confidence
Mentioned
$TLRY
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TLRYNeutralLow
01

Why it matters

The disclosed open-market purchase by the company’s Global General Counsel may be interpreted as mild positive sentiment, but it does not provide new company performance, strategy, or regulatory information.

02

Market read

Traders may note the insider buying signal, but the filing lacks fundamental catalysts and is unlikely to drive sustained repricing alone.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide context like prior holdings changes or option exercises.

Relevance 4/10Novelty 5/10Timing: Form 4 filed 2026-08-07, covering purchase dated 2026-08-06.

Background

The article is an SEC Form 4 insider transaction disclosure for Tilray Brands, Inc.

Company-level read

Ticker impact

$TLRYNeutralLow confidence
Context

Tilray insider Gendel Mitchell bought 2,500 shares at $4.43 on 2026-08-06, disclosed via Form 4 filed 2026-08-07.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing is a routine Form 4 transaction with no 10b5-1 plan and no accompanying corporate event, guidance, or operational change.

Market effects

No clear sector read-through from a single legal counsel purchase.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary and may reflect diversification or personal liquidity needs rather than a bullish view on near-term fundamentals.

Key entities

  • Tilray Brands, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Gendel Mitchell

    Global General Counsel who purchased 2,500 shares at $4.43 on 2026-08-06.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

$TLRYMed

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray Brands reported record fiscal 2026 revenue of $915 million, up 11%, and adjusted EBITDA of $61.1 million, also up 11%. Adjusted net income nearly doubled to $12.2 million, but missed analyst estimates. GAAP net loss was $49.6 million. Management expects fiscal 2027 adjusted EBITDA of $68M-$75M. Cannabis sales represent 29% of total revenue.

$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.